UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 410

Sortiert nach

111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure : A clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. Commentary

European journal of cancer (1990), 2007, Vol.43 (14)

2007

Volltextzugriff (PDF)

118 Does delayed gastric emptying predispose to gastrooesophageal reflux in preterm infants?

Journal of pediatric gastroenterology and nutrition, 1994-10, Vol.19 (3), p.358

1994

Volltextzugriff (PDF)

118 Does delayed gastric emptying predispose to gastrooesophageal reflux in preterm infants?

Journal of pediatric gastroenterology and nutrition, 1994-10, Vol.19 (3), p.358-358

1994

Volltextzugriff (PDF)

1197 Outcomes of Surgically Treated Babies with Gastroschisis- a 10 Year Experience

Pediatric research, 2010-11, Vol.68, p.592-592

2010

Volltextzugriff (PDF)

1202 Outcomes of Babies with Severe Rhesus Disease Following In-Utero Transfusions - a 10 Year Experience

Pediatric research, 2010-11, Vol.68, p.594-595

2010

Volltextzugriff (PDF)

199OLong-term cardiac outcomes of HER2+ breast cancer patients treated in the ALTTO trial

Annals of oncology, 2019-05, Vol.30 (Supplement_3)

2019

Volltextzugriff (PDF)

2009 POSTER Safety of the combination of lapatinib (L) plus trastuzumab (T) in patients (pts) with HER2-Positive (+) metastatic breast cancer (MBC)

European journal of cancer supplements, 2007, Vol.5 (4), p.187-187

2007

Volltextzugriff (PDF)

2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines

European journal of heart failure, 2017-01, Vol.19 (1), p.9-42

2017

Volltextzugriff (PDF)

2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)

European journal of heart failure, 2017-01, Vol.19 (1), p.9-42

2017

Volltextzugriff (PDF)

208 EFFECTS OF NG-METHYL-ARGININE IN CLINICAL SHOCK

Shock (Augusta, Ga.), 1995-05, Vol.3 (5), p.64

1995

Volltextzugriff (PDF)

250 CARDIOVASCULAR TOXICITY FOLLOWING SUNITINIB THERAPY IN METASTATIC RENAL CELL CANCER: A MULTICENTER RETROSPECTIVE ANALYSIS

European urology supplements : official journal of the European Association of Urology, 2009-03, Vol.8 (4), p.183-183

2009

Volltextzugriff (PDF)

43O Pertuzumab/trastuzumab in early stage HER2-positive breast cancer: 5-year and final analysis of the BERENICE trial

Annals of oncology, 2021-05, Vol.32, p.S38-S39

2021

Volltextzugriff (PDF)

5‐Fluorouracil, adriamycin, and mitomycin‐C (Hi‐FAM) chemotherapy for adenocarcinoma of the lung

Cancer, 1981-07, Vol.48 (1), p.21-25

1981

Volltextzugriff (PDF)

Abstract 14843: Electrocardiographic Manifestations of Immune Checkpoint Inhibitor Associated Myocarditis

Circulation (New York, N.Y.), 2020-11, Vol.142 (Suppl_3 Suppl 3), p.A14843-A14843

2020

Volltextzugriff (PDF)

Abstract OT3-1-01: A two-cohort, phase II, cardiac safety study of pertuzumab, trastuzumab, and neoadjuvant anthracycline-based chemotherapy in patients with HER2-positive, locally advanced, inflammatory, or early breast cancer

Cancer research (Chicago, Ill.), 2015-05, Vol.75 (9_Supplement), p.OT3-1-01-OT3-1-01

2015

Volltextzugriff (PDF)

Abstract P1-14-02: Disease-free (DFS) and overall survival (OS) data from ACOSOG Z1041 (Alliance) a randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T → FEC+T) in HER2-positive operable breast cancer

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P1-P1-14-02

2016

Volltextzugriff (PDF)

Abstract P4-21-09: Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2 positive early breast cancer (BIG 1-06)

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P4-P4-21-09

2017

Volltextzugriff (PDF)

Abstract P4-21-41: Primary analysis of BERENICE: A phase II cardiac safety study of pertuzumab, trastuzumab, and neoadjuvant anthracycline-based chemotherapy in patients with locally advanced, inflammatory, or early-stage, unilateral, and invasive HER2-positive breast cancer

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P4-P4-21-41

2017

Volltextzugriff (PDF)

Abstract P5-20-04: Safety of adjuvant treatment with pertuzumab plus trastuzumab after neoadjuvant anthracycline-based chemotherapy in patients with HER2-positive localized breast cancer: Updated results from the BERENICE study

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P5-P5-20-04

2018

Volltextzugriff (PDF)

Abstracts for the British Congenital Cardiac Association Annual Meeting: The Barbican, London, 24–25 November 2005: Poster Presentations: 8 Years of fetal echocardiography in high-risk mothers: The Birmingham Women’s Hospital experience

Cardiology in the young, 2006-06, Vol.16 (3), p.322-323

2006

Volltextzugriff (PDF)

Acid oro-pharyngeal secretions can predict gastro-oesophageal reflux in preterm infants

European journal of pediatrics, 1999-05, Vol.158 (5), p.371-374

1999

Volltextzugriff (PDF)

Adriamycin therapy by continuous intravenous infusion in patients with metastatic breast cancer

Cancer, 1982-05, Vol.49 (9), p.1762-1766

1982

Volltextzugriff (PDF)

Advance directives in the intensive care unit of a tertiary cancer center

Cancer, 1995-10, Vol.76 (7), p.1268-1274

1995

Volltextzugriff (PDF)

Alcohol septal ablation for left ventricular outflow tract obstruction in cardiac amyloidosis: New indication for an established therapy

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2022, Vol.100 (5), p.910-914

2022

Volltextzugriff (PDF)

1 – 25 von 410

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(353)
Mit Volltextzugriff
(335)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(408)
Japanisch
(45)
Deutsch
(2)
Spanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure : A clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. Commentary

118 Does delayed gastric emptying predispose to gastrooesophageal reflux in preterm infants?

118 Does delayed gastric emptying predispose to gastrooesophageal reflux in preterm infants?

1197 Outcomes of Surgically Treated Babies with Gastroschisis- a 10 Year Experience

1202 Outcomes of Babies with Severe Rhesus Disease Following In-Utero Transfusions - a 10 Year Experience

199OLong-term cardiac outcomes of HER2+ breast cancer patients treated in the ALTTO trial

2009 POSTER Safety of the combination of lapatinib (L) plus trastuzumab (T) in patients (pts) with HER2-Positive (+) metastatic breast cancer (MBC)

2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines

2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)

2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)

208 EFFECTS OF NG-METHYL-ARGININE IN CLINICAL SHOCK

250 CARDIOVASCULAR TOXICITY FOLLOWING SUNITINIB THERAPY IN METASTATIC RENAL CELL CANCER: A MULTICENTER RETROSPECTIVE ANALYSIS

43O Pertuzumab/trastuzumab in early stage HER2-positive breast cancer: 5-year and final analysis of the BERENICE trial

5‐Fluorouracil, adriamycin, and mitomycin‐C (Hi‐FAM) chemotherapy for adenocarcinoma of the lung

Abstract 14843: Electrocardiographic Manifestations of Immune Checkpoint Inhibitor Associated Myocarditis

Abstract OT3-1-01: A two-cohort, phase II, cardiac safety study of pertuzumab, trastuzumab, and neoadjuvant anthracycline-based chemotherapy in patients with HER2-positive, locally advanced, inflammatory, or early breast cancer

Abstract P4-21-09: Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2 positive early breast cancer (BIG 1-06)

Abstract P4-21-41: Primary analysis of BERENICE: A phase II cardiac safety study of pertuzumab, trastuzumab, and neoadjuvant anthracycline-based chemotherapy in patients with locally advanced, inflammatory, or early-stage, unilateral, and invasive HER2-positive breast cancer

Abstract P5-20-04: Safety of adjuvant treatment with pertuzumab plus trastuzumab after neoadjuvant anthracycline-based chemotherapy in patients with HER2-positive localized breast cancer: Updated results from the BERENICE study

Abstracts for the British Congenital Cardiac Association Annual Meeting: The Barbican, London, 24–25 November 2005: Poster Presentations: 8 Years of fetal echocardiography in high-risk mothers: The Birmingham Women’s Hospital experience

Acid oro-pharyngeal secretions can predict gastro-oesophageal reflux in preterm infants

Adriamycin therapy by continuous intravenous infusion in patients with metastatic breast cancer

Advance directives in the intensive care unit of a tertiary cancer center

Alcohol septal ablation for left ventricular outflow tract obstruction in cardiac amyloidosis: New indication for an established therapy

Suchergebnisse filtern